Abivax S.A. (ABVX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Is Abivax S.A. stock overvalued or undervalued in 2026?
As of November 3, 2026, Abivax S.A. (ABVX) trades at $88.71 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Abivax S.A.
Market cap $8B · 52 weeks $72 – $145 (42 % below the high) · P/E no earnings · Dividend none · Next earnings December 21, 2026 · expected EPS -$0.92 · Closing price, Nov 3 · accounts published Sep 21.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 11.6×, fails.
- Cash Runway 41 months, passes.
- Total Debt 0.1×, passes.
- Annual cash burn $2.24, info.
Against its peers (reference peers) — Abivax S.A.: P/E —; EV/EBITDA —; ROIC -61.0 %; $7.8B. Nurix Therapeutics, Inc. (P/E 11.2×; EV/EBITDA 6.7×; ROIC 25.9 %; $2.8B), Krystal Biotech, Inc. (P/E 41.4×; EV/EBITDA 34.4×; ROIC 15.8 %; $9.0B), Protagonist Therapeutics, Inc. (P/E 136×; EV/EBITDA 100×; ROIC 6.7 %; $9.1B).
Profitability
| Return on Equity | -85.88% |
| Return on Invested Capital | -60.98% |
| Return on Assets | -76.32% |
| Gross Margin | 153.15% |
| Operating Margin | 11,950.42% |
| Net Margin | 17,488.89% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.97 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 34.93 |
Price Performance
| 1 month | -7.43% |
| 3 months | -34.68% |
| Year-to-date | -37.03% |
| 1 year | -13.92% |
| 3 years | +740.69% |
Related companies: SYRE · NRIX · RCUS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of ABVX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks